Cerecor Signs a Worldwide License Agreement with Kyowa Kirin for CERC-00

 Cerecor Signs a Worldwide License Agreement with Kyowa Kirin for CERC-00

Cerecor Signs a Worldwide License Agreement with Kyowa Kirin for CERC-00

Shots:

  • Kyowa Kirin to receive up front, regulatory & commercial milestones along with royalties and a share of sublicensing income. The company also has an option to retain rights in Japan
  • Cerecor to get exclusive rights for the development, manufacturing and commercialization of CERC-00 for all indications globally including the US, EU and Japan
  • The expanded agreement involves all indications of CERC-00 including severe pediatric onset inflammatory bowel disease and ARDS (including COVID-19 ARDS)

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Bio Tuesdays

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post